Biomea Fusion, Inc. Common Stock
BMEA Real Time Price USDRecent trades of BMEA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in BMEA holdings by institutional investors
Quarterly net insider trading by BMEA's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
BMEA Estimated quarterly lobbying spending
BMEA Revenue by Segment or Geography
New BMEA patent grants
-
Patent Title: Inhibitors of menin-mll interaction Apr. 15, 2025
-
Patent Title: Covalent inhibitors of menin-mll interaction for diabetes mellitus Mar. 18, 2025
-
Patent Title: Crystalline forms of n[4[4-(4-morpholinyl)-7h-pyrrolo[2-3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-protein-1-yl)amino]-1-piperidinyl]methyl]2-pyridinecarboxamide] Feb. 04, 2025
-
Patent Title: Substituted pyridines as irreversible inhibitors of menin-mll interaction Oct. 15, 2024
-
Patent Title: Irreversible inhibitors of menin-mll interaction Sep. 03, 2024
-
Patent Title: Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-mll interaction Jun. 25, 2024
-
Patent Title: Pyrazine compounds as inhibitors of flt3 Apr. 02, 2024
-
Patent Title: Inhibitors of menin-mll interaction Dec. 19, 2023
-
Patent Title: Substituted pyridines as irreversible inhibitors of menin-mll interaction Jul. 18, 2023
-
Patent Title: Inhibitors of menin-mll interaction Nov. 16, 2021
-
Patent Title: Substituted pyridines as irreversible inhibitors of menin-mll interaction Aug. 10, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded to BMEA from public contracts
Recent insights relating to BMEA
Recent picks made for BMEA stock on CNBC
ETFs with the largest estimated holdings in BMEA
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BMEA stock a Buy, Sell, or Hold?
- What is the price target for $BMEA stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BMEA stock?
- Who owns the most shares of $BMEA stock?
- What funds own $BMEA stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BMEA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
- Address San Carlos, CA
- Market Cap 77.8 million
- Employees 42
- Industrial Classification Pharmaceutical Preparations